The First of Five Architectural Masterpieces at The Case, Malibu’s Only New Guard Gate Community in Decades, Lists for $69.995 Million
16.6.2022 00:51:00 EEST | Business Wire | Press release
After more than a decade in approvals, design, and construction, Scott Gillen, visionary home designer, creator and founder of Unvarnished, has listed for sale the first of five estates in the 24-acre private enclave known as The Case. The first guard gated community built in Malibu in decades, The Case comprises five spectacular mid-century modern inspired homes perched above The Colony on Malibu’s most coveted oceanfront bluff and represents the largest private residential development in its history. The Edge, on the market for $69.995 million, will be the first home completed within the community and will be delivered turnkey, providing the buyer instant gratification of unprecedented luxury and hand-crafted design perfection. All five bespoke homes are currently under construction, with the remaining homes slated for full completion throughout the year.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220615006048/en/
The Edge (Photo: Business Wire)
“The Case is my largest and most epic project to date. The opportunity to create a community of five homes on one of, if not the best bluff top on the California coast, was something I could not pass up. Frankly, ten minutes after I stepped on the property, I knew I would buy it,” said Scott Gillen, the founder of Unvarnished. “The sheer size of the property and the ability to build 10,000 to 12,000-square foot single story homes created immense challenges and unbelievable opportunities for me to take some of my foundational design principles--use of warm natural materials, a nod toward mid-century modern, large, opened spaces, lots of natural light and blurring the line between indoors and out-- which are also tenets of mid-century modern architecture--to the next level. So, it was natural that my designs for The Edge, and the other homes at The Case, take enormous inspiration from mid-century modern architecture, and then I incorporate construction techniques and furnishings, the quality of which are rarely, if ever, found in new development, to create a unique experience of luxury living on the coast of Malibu, a place unlike anywhere else in the world. I’m very proud of how The Edge has turned out and I’m incredibly excited to bring it to market.”
The 2.6-acre estate, providing cinematic views of the Queen’s necklace, Palos Verdes to Point Dume, embodies the essence of casual luxury living. Spanning approximately 10,500 square feet, the single-story home offers five ensuite bedrooms and three half baths, and includes a Bulthaup chef’s kitchen, expansive great room, a master bedroom with outdoor spa, and floor to ceiling glass doors that open to a 10,000-square foot Ipe deck with cabana and outdoor kitchen.
The Edge, named for its stunning nearly 80-foot double-sided infinity edge freshwater pool that juts out like a diving board into the Pacific Ocean, with famed Catalina Island in the distance, is architecturally inspired by the giants of mid-century modern, Lloyd Wright, Neutra, Lautner and Quincy Jones, to name but a few. The magnificent home also includes hand-picked custom furnishings by Minotti and Gillen, Miele and Gaggenau appliances, custom cabinets, a 650-bottle teak wine room, a glass and teak enclosed private library, and a home theatre that is a room “floating” inside another room to achieve the ultimate home cinema experience.
The Case is the crown jewel of Scott Gillen’s visionary Malibu Series, where each home is a sanctuary unto itself. Behind its 24-hour manned guard gate and security features designed by international renowned security expert Gavin de Becker, residents of The Case will live with ultimate peace of mind and privacy.
The Case comprises five distinct mid-century modern homes: The Cantilever House (Case Study No. 1), The Butterfly House (Case Study No. 2), The Edge (Case Study No. 3), The Flat House (Case Study No. 4) and The Glass Tunnel (Case Study No. 5).
For more information, visit www.unvarnishedco.com or contact listing agent Sandro Dazzan of The Agency.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220615006048/en/
Contact information
Emily Warner
Murphy O’Brien Public Relations
unvarnishedcopr@murphyobrien.com
310.453.2539
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 15:05:00 EEST | Press release
A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is designed to interpret cardiac MRI scans by connecting moving images of the heart with corresponding clinical radio
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 15:00:00 EEST | Press release
Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The research challenges long-held assumptions about media value, showing that not all impressions are equal. Live sports rem
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 15:00:00 EEST | Press release
Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer cell killing activity,” said David Weinreich, MD, MBA, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “The Phase 3 study and the enrollment of the first patient with Precem-TcT build on the Company’s more than 20 years of expertise in colorectal cancer, and highlight our commitment to advancing differentiated ADCs for heavily pretreated patients with limited treatment options.” The PROCEADE®-CRC-03 study
Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 14:00:00 EEST | Press release
Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early, subtle symptoms. Individuals in this stage, classified as CHR-P, represent a critical pr
SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend21.5.2026 13:30:00 EEST | Press release
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has extended the deadline for shareholders and nominee brokers to submit payment instructions relating to the Company’s previously declared special cash dividend. The Company previously announced a special cash dividend of US$55.00 per common share, payable to valid holders of the Company’s common shares as of the close of business on May 23, 2025 ET. The Company previously informed shareholders that completed instruction materials were to be submitted prior to December 31, 2025 in order to facilitate receipt of the dividend. The Company has now extended that submission deadline to June 30, 2026. Shareholders and nominee brokers that have not yet submitted their instruction materials are reminded to do so on or before June 30, 2026 in order to facilitate payment of the dividend. If you have any questions regarding the process you need to un
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
